Case Series of Primaquine-Induced Haemolytic Events in Controlled Trials with G6PD Screening
Details
Publication Year 2023-09-19,Volume 1176,Issue #9,Page 1176
Journal Title
Pathogens
Abstract
Primaquine for radical cure of Plasmodium vivax malaria poses a potentially life-threatening risk of haemolysis in G6PD-deficient patients. Herein, we review five events of acute haemolytic anaemia following the administration of primaquine in four malaria trials from Indonesia, the Solomon Islands, and Vietnam. Five males aged 9 to 48 years were improperly classified as G6PD-normal by various screening procedures and included as subjects in trials of anti-relapse therapy with daily primaquine. Routine safety monitoring by physical examination, urine inspection, and blood haemoglobin (Hb) assessment were performed in all those trials. Early signs of acute haemolysis, i.e., dark urine and haemoglobin drop >20%, occurred only after day 3 and as late as day 8 of primaquine dosing. All patients were hospitalized and fully recovered, all but one following blood transfusion rescue. Hb nadir was 4.7 to 7.9 g/dL. Hospitalization was for 1 to 7 days. Hb levels returned to baseline values 3 to 10 days after transfusion. Failed G6PD screening procedures in these trials led G6PD-deficient patients to suffer harmful exposures to primaquine. The safe application of primaquine anti-relapse therapy requires G6PD screening and anticipation of its failure with a means of prompt detection and rescue from the typically abrupt haemolytic crisis.
Publisher
MDPI
Keywords
G6PD deficiency; G6PD screening; acute haemolytic anaemia; primaquine; randomized controlled trials
Research Division(s)
Population Health And Immunity
PubMed ID
37764985
Open Access at Publisher's Site
https://doi.org/0.3390/pathogens12091176
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2023-11-15 10:47:41
Last Modified: 2023-11-15 10:59:30
An error has occurred. This application may no longer respond until reloaded. Reload 🗙